# Xeris Biopharma Holdings (XERS): Growth Potential and Analyst Consensus Highlight a 37% Upside

- Link: https://www.directorstalkinterviews.com/xeris-biopharma-holdings-xers-growth-potential-and-analyst-consensus-highlight-a-37-upside/4121234163
- Published: 2026-01-09T11:30:30+00:00
- Author: Madison Wilson

Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) is drawing significant attention in
the biotechnology sector, with a market cap of $1.35 billion and a strong focus 
on developing therapies for chronic endocrine and neurological diseases. Headquartered
in Chicago, Illinois, the company is renowned for its innovative products, including
Gvoke, Keveyis, and Recorlev, each serving critical medical needs ranging from severe
hypoglycemia to Cushing’s syndrome.

Currently trading at $8.13, Xeris Biopharma has seen a price change of 0.92, marking
a 0.13% increase. The company’s stock price has fluctuated within a 52-week range
of $3.20 to $9.90, suggesting potential volatility but also room for growth. This
is further supported by the analyst consensus, which shows six buy ratings and a
single hold rating, with zero sell ratings. The average target price stands at $
11.14, indicating a potential upside of approximately 37.06% from its current level.

Despite the lack of a trailing P/E ratio and other standard valuation metrics, Xeris
is showing promising signs of growth. The forward P/E ratio is a noteworthy 25.85,
suggesting that investors are optimistic about future earnings. With revenue growth
at an impressive 37.10%, the company is demonstrating strong operational performance,
although it currently reports a negative EPS of -0.10, reflecting ongoing investments
in research and development.

Xeris Biopharma’s financial health is further supported by a free cash flow of $
28.55 million, a vital indicator of the company’s ability to finance its operations
and future growth initiatives. While the company does not offer dividends, the focus
remains on reinvesting earnings to fuel innovation and expansion in its product 
lines.

From a technical standpoint, the stock shows a 50-day moving average of $7.53 and
a 200-day moving average of $6.39, both of which indicate positive momentum. The
relative strength index (RSI) of 58.51 suggests that the stock is neither overbought
nor oversold, providing a stable foundation for potential investors.

Xeris Biopharma’s pipeline, particularly the XP-8121, a weekly subcutaneous injection
for hypothyroidism currently in phase 3 clinical trials, presents additional growth
opportunities. The successful commercialization of this drug could further enhance
the company’s revenue streams and market position.

For investors seeking opportunities in the biopharmaceutical sector, Xeris Biopharma
offers a compelling case with its robust product lineup, significant potential upside,
and strong analyst endorsement. While the company navigates the complexities of 
bringing innovative therapies to market, its current trajectory suggests promising
long-term growth prospects.

Share on: